Search

Clarence K Yap

from San Francisco, CA
Age ~45
Get Report
Related to:
Jeremy Kam-Hon Yap, 42Marie FreemanHui XuJoanna Choi
Connected to:
Abegale A Yap, 46Abel J Yap, 43Ai C Yap, 61Aimee E Yap, 54Amalia R Yap, 66Amy Yap, 44Angelina G Yap, 85Annette K Yap, 61Aye M Yap, 53Bobby L Yap, 63

Clarence Yap Phones & Addresses

  • 770 42Nd Ave, San Francisco, CA 94121 (415) 387-2854
  • 305 50Th St, New York, NY 10019
  • 244 Pearson St, Chicago, IL 60611 (312) 751-9204
  • Evanston, IL

Resumes

Resumes

Clarence Yap Photo 1

Head Of Hemoglobinopathy Cell Therapy, Product Development

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Sangamo Therapeutics
Head of Hemoglobinopathy Cell Therapy, Product Development
Biomarin Pharmaceutical Inc. 2016 - 2019
Senior Director, Product Portfolio Development
Biomarin Pharmaceutical Inc. 2010 - 2016
Director, Product Development
Biomarin Pharmaceutical Inc. 2008 - 2010
Associate Director Product Development
Biomarin Pharmaceutical Inc. 2006 - 2008
Senior Manager, Program Management
Education:
Northwestern University
Bachelors, Bachelor of Science, Biomedical Engineering, Education Northwestern University - the Feinberg School of Medicine
Doctor of Medicine, Doctorates, Education, Medicine Northwestern University
Master of Public Health, Masters, Public Health Harvard Business School
Crescent School
Clarence Yap Photo 2

Clarence Yap

View page

Publications

Us Patents

Use Of C-Type Natriuretic Peptide Variants To Treat Skeletal Dysplasia

View page
US Patent:
20180207239, Jul 26, 2018
Filed:
Jan 25, 2018
Appl. No.:
15/880002
Inventors:
- NOVATO CA, US
STUART BUNTING - NOVATO CA, US
TIANWEI CHOU - NOVATO CA, US
AUGUSTUS O. OKHAMAFE - CONCORD CA, US
CHRISTOPHER P. PRICE - MUNICH, DE
DANIEL J. WENDT - NOVATO CA, US
CLARENCE YAP - NOVATO CA, US
Assignee:
BIOMARIN PHARMACEUTICAL INC. - NOVATO CA
International Classification:
A61K 38/22
A61K 47/26
A61K 47/18
A61K 47/12
A61K 9/00
A61K 38/17
A61K 9/19
A61K 47/10
Abstract:
The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.

Use Of C-Type Natriuretic Peptide Variants To Treat Skeletal Dysplasia

View page
US Patent:
20170028023, Feb 2, 2017
Filed:
Aug 1, 2016
Appl. No.:
15/225355
Inventors:
- Novato CA, US
Stuart Bunting - Novato CA, US
Tianwei Chou - Novato CA, US
Augustus O. Okhamafe - Concord CA, US
Christopher P. Price - Aachen, DE
Daniel J. Wendt - Novato CA, US
Clarence Yap - Novato CA, US
International Classification:
A61K 38/22
A61K 47/12
A61K 9/00
A61K 47/18
A61K 47/10
A61K 9/19
A61K 47/26
Abstract:
The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
Control profile
Clarence K Yap from San Francisco, CA, age ~45 Get Report